Fiona Simpkins is an Oncology physician affiliated with University of Pennsylvania Health System. OpenAlex indexes 361 publications with 3,969 citations (h-index 35); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3400 Civic Center Blvd
3rd Floor
Philadelphia, PA 19104
Telephone
215-662-3318Registry record last updated 18 Oct 2019.
Clinical trials
- Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
Sponsor: National Cancer Institute (NCI)
- Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer
Sponsor: University of Pennsylvania
- Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Sponsor: Abramson Cancer Center at Penn Medicine
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- BeiGene USA, Inc.Program year20241 payment
- AstraZeneca Pharmaceuticals LPProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
4 NIH research awards on record, funded 2014–2026 per NIH RePORTER. The latest:
- Developing biomarkers of response for a new therapy in ovarian cancer
University of Pennsylvania
FY2026$676,415R01CA285965 - Platform to develop targeted therapies for aggressive less common gynecological cancers
University of Pennsylvania
FY2026$256,669U54CA283759 - Developing biomarkers of response for a new therapy in ovarian cancer
University of Pennsylvania
FY2025$676,860R01CA285965
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR
Nature Communications
2025 - Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancers
npj Precision Oncology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Jerome Strauss, MD, PhD
University of Pennsylvania Health System
Arthur Staddon, MD
University of Pennsylvania Health System
Keith Calligaro, MD
University of Pennsylvania Health System
Christopher Rassekh, MD
University of Pennsylvania Health System
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”